Daniel Simon

Daniel Simon serves as Chief Business Officer at IDEAYA Biosciences. IDEAYA Biosciences operates in the research sector with approximately 190.0 employees. The company is headquartered in Portola Valley, California. IDEAYA Biosciences generates annual revenue of 7000000.0.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • 13,743 executive contacts are available in California.
• • Our database includes 201,469 c suite-level executives.

NetSuite Amazon SES Sendgrid Mimecast Outlook MailChimp SPF Microsoft Office 365 WP Engine OneTrust Remote

synthetic lethality & precision medicine biotechnology: pharmaceutical preparations health care biotechnology research precision medicine oncology targeted therapeutics molecular diagnostics synthetic lethality clinical-stage biomarker discovery cancer drug development early discovery clinical trials therapeutic window gnaq mutations gna11 mutations mat2a inhibition parg inhibition homologous recombination deficiency translational biology tumor biology crispr gene editing tumor profiling small molecule inhibitors protein kinase c biomarker selection expanded access solid tumors therapeutic efficacy genetic alterations cell viability tumor microenvironment drug discovery platform first-in-class therapeutics best-in-class therapeutics clinical trial collaboration combinatorial therapies investigational drugs pharmacological inhibition fda approval oncogenic pathways tumor suppressor genes vulnerability targeting therapeutic candidates advanced solid tumors molecular biology patient stratification collaborative research biopharma partnerships regulatory compliance therapeutic strategies cancer treatment personalized therapy adult cancer patients genetic vulnerabilities drug discovery clinical-stage programs biomarker-driven development innovative therapeutics healthcare providers pharmaceutical collaborations genetic profiling advanced cancer therapies unmet medical needs ai-driven drug discovery oncology research patient-centered approach therapeutic pipeline cancer biomarkers precision oncology therapeutic innovation cancer patient demographics biotechnology pharmaceuticals global healthcare access cancer research partnerships health wellness & fitness hospital & health care medical

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like Daniel Simon in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at IDEAYA Biosciences.

How do I reach Daniel Simon directly?

Daniel Simon's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Business Officer at IDEAYA Biosciences. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Daniel Simon work for?

Daniel Simon is Chief Business Officer at IDEAYA Biosciences, a company in the research sector with 190.0 employees. The company is based in Portola Valley, California.

Can I pitch or sell to Daniel Simon?

As Chief Business Officer at IDEAYA Biosciences, Daniel Simon is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Daniel Simon directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Daniel Simon in?

Daniel Simon works in the research industry as Chief Business Officer at IDEAYA Biosciences. MessageCEO provides verified contact information for executives across all major industries.

Is Daniel Simon's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Daniel Simon's profile is kept up-to-date with the latest available information.

Last updated: May 12, 2026